Multi-drug resistant pulmonary tuberculosis

Current Respiratory Medicine Reviews

Volumn 2, Issue 1, 2006, Pages 53-57

  Joshi, J M ^a   Gothi, D ^a  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

Author keywords

Laboratory errors; Multidrug resistant tuberculosis; Second line therapy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; AZITHROMYCIN; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MACROLIDE; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; ROXITHROMYCIN; STREPTOMYCIN; THIOACETAZONE; THIOAMIDE; TUBERCULOSTATIC AGENT;

ACNE; ANTIBIOTIC SENSITIVITY; ANXIETY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PROTOCOL; DEPRESSION; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; GASTROINTESTINAL SYMPTOM; GOITER; GYNECOMASTIA; HEADACHE; HEALTH CARE COST; HEARING IMPAIRMENT; HEPATITIS; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; IMPOTENCE; LUNG TUBERCULOSIS; MENSTRUATION DISORDER; MOOD DISORDER; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATIENT REFERRAL; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; REVIEW; SHORT COURSE THERAPY; SLURRED SPEECH; TREATMENT FAILURE; VERTIGO; WORLD HEALTH ORGANIZATION;

EID: 33745840164     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339806775486146     Document Type: Review

References (28)

1. Veen J. Drug resistant tuberculosis back to sanatoria, surgery and cod liver oil. Eur Respir J 1995; 8: 1073-7
2. Tuberculosis: A global emergency. World Health Forum 1993; 14:438.
3. Sandman L, Schluger N W, Davidow A L, Bank S. Risk factors for Rifampin- monoresistant tuberculosis. Am J Respir Crit Care Med 1999,159; 468-472.
4. Stefan G, Andrew V, William B, et al. Acquired rifamycin monoresistance in patients with HIV- related tuberculosis treated with once- weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-47.
5. Treatment of tuberculosis. Guidelines for National Programmes Third Edition. WHO 2003. Geneva, WHO/CDS/TB 2003.313.
6. WHO/CDS/TB/2003.313 Treatment of tuberculosis: guidelines for national programmes, third edition. Revised June 2004. WHO/HTM/TB/2004.343.
7. DOTS-Plus Green Light Committee WHO/CDS/TB/2000.283.
8. Pablos-Mendez A, Biokin N, Rieder HL, et al. Global surveillance for anti-tuberculosis drug resistance, 1994 - 1997. World Health Organization - International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Eng. J. Med. 1998; 338: 1641-1650.
9. Anti-tuberculosis drug resistance in the world. WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance Executive Summary Third Global Report. WHO/HTM/TB/2004.303
10. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis. WHO / TB / 96.210.
11. Drobniewski FA. Is death inevitable with multiresistant TB plus HIV infection? Lancet 1997; 349:71-72.
12. Burman W J, Jones B E. Treatment of HIV-related tuberculosis in the era of effective anti-retroviral therapy. Am J Respir Crit Care Med 2001; 164:7-12.
13. Tenover FC, Crawford JT, Heubner RE, Ceiter LF, Harsburgh CR, Good RC. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993; 31:767-770.
14. Nitta AT, Davidson PT, deKong ML, Kilman RJ. Misdiagnosis of multidrug resistant tuberculosis possibly due to laboratory related errors. JAMA 1996: 276: 1980-1983.
15. Vareldiz BP, Grusse J de Kantor I, Crofton J, et al. Drug resistance tuberculosis: laboratory issues. Tubercle and Lung Diseases 1994; 75:1-7.
16. Singla R, Myneedu VP, Jaiswal A, et al. Ethionamide, Cycloserine, Isoniazid, Sodium PAS and Kanamycin in retreatment of drug failure pulmonary tuberculosis patients. Indian Journal of Tuberculosis 1995; 42: 23-26.
17. Geerligs WA, Altena RV, Werf TS. Antituberculosis Drug Resistance Correspondence. N Eng J Med 1998; 339: 1079-80.
18. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. Int J Tuberc Lung Dis 1998; 2: 877-84
19. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001 Jul 19; 345(3):170-4
20. Chan ED, Laurel V, Strand MJ, et al. Treatment and Outcome Analysis of 205 Patients with Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2004 Jan 23 [Epub ahead of print].
21. Davidson PT, Le HQ. Drug treatment of tuberculosis. Drugs 1992; 43: 651-73.
22. Iseman MD, Youngchaiyud P. Update treatment of multi drug resistant tuberculosis, Proceedings of a sponsored symposium to the 29th world conference of the IUATLD / UICTMR. Bangkok, Thailand, 1998.
23. Di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004; 54:593-602. Epub 2004 Jul 28.
24. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8:1012-6.
25. Ormerod P. More carrot or more stick or both? Thorax Editorial 1999; 54: 95-97.
26. Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Smith Fawzi MC, Shin S. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8:749-59.
27. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost effectiveness of standardized second line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
28. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-7.